Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22020244 | 0.88 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL21962113 | 0.88 | — | — | |
| SCHEMBL20681230 | 0.88 | CA2 (0.33) | CA2CA12CA1CA9CA14 | |
| SCHEMBL22015028 | 0.84 | NLRP3 (0.34) | NLRP3 | |
| SCHEMBL21963198 | 0.82 | NLRP3 (0.30) | NLRP3 | |
| SCHEMBL22021435 | 0.77 | — | — | |
| SCHEMBL24116130 | 0.77 | NLRP3 (0.38) | CA2CA12CA1CA9CA14 | |
| SCHEMBL21962381 | 0.77 | CA2 (0.32) | CA2 | |
| SCHEMBL24978527 | 0.77 | CA2 (0.32) | CA2 | |
| SCHEMBL21962387 | 0.77 | CA2 (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20220267276-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2022-08-25 | — | — | US | disclosed |
| US-20210395241-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210395241-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| CN-113613721-A | NLRP modulators | 诺华股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3817815-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| EP-3817817-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| CN-112584899-A | NLRP modulators | 诺华股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1245/4885CA12 2839/4885CA1 3665/4885 |
| US-20210395241-A1 | NLRP MODULATORS | NLRP1, NLRP3, NOD1 | CA2 1928/4885CA12 3494/4885CA1 4414/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1522/4885CA12 3011/4885CA1 3832/4885 |
| US-20220267276-A1 | NLRP MODULATORS | NLRP1, NRP1, NR4A3 | CA2 2463/4885CA12 3442/4885CA1 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.